Article Information
PubMed
Print ISSN
Online ISSN
History
- Received August 17, 2007
- Accepted January 23, 2008
- Published online March 17, 2008.
Article Versions
- Earlier version (January 24, 2008 - 11:20).
- You are viewing the most recent version of this article.
Copyright & Usage
The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Andrew J. Hirsh,
- Jim Zhang,
- Andra Zamurs,
- Jacquelyn Fleegle,
- William R. Thelin,
- Ray A. Caldwell,
- Juan R. Sabater,
- William M. Abraham,
- Mark Donowitz,
- Boyoung Cha,
- Kevin B. Johnson,
- Judith A. St. George,
- M. Ross Johnson and
- Richard C. Boucher
- Parion Sciences Inc., Durham, North Carolina (A.J.H., A.Z., J.F., K.B.J., J.A.S.G., M.R.J.); Albany Molecular Research Inc., Albany, New York (J.Z.); Cystic Fibrosis/Pulmonary Research and Treatment Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (W.R.T., R.A.C., R.C.B.); Division of Pulmonary and Critical Care Medicine, University of Miami at Mount Sinai Medical Center, Miami Beach, Florida (J.R.S., W.M.A.); and Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland (M.D., B.C.)
- Address correspondence to:
Dr. Andrew J. Hirsh, Parion Sciences Inc., 2525 Meridian Pkwy., Suite 260, Durham, NC 27713. E-mail: ajhirsh{at}parion.com
Statistics from Altmetric.com
Article usage
In this issue
Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement